Board of Directors
John LaMattina, PhD
Chairman of the Board
During Dr. LaMattina’s leadership tenure Pfizer discovered and/or developed a number of important new medicines including Tarceva, Chantix, Zoloft (PTSD), Selzentry and Lyrica along with a number of other medicines currently in late stage development for cancer, rheumatoid arthritis and pain. He is the author of numerous scientific publications and U.S. patents. In addition, Dr. LaMattina is the author of “Drug Truths: Dispelling the Myths About Pharma R&D”. Dr. LaMattina has received numerous awards and honors including the American Diabetes Association Award for Leadership and Commitment in the Fight Against Diabetes. Dr. LaMattina serves on the Board of Directors of PureTech Ventures, Human Genome Sciences and Neurogen and serves as Chairman of the Strategic Advisory Committee for Bilcare. He also is a member of the Board of Trustees of Boston College.
CEO & Founder, Gelesis
Mr. Zohar is the Founder and Chief Executive Officer of Gelesis Inc., a Boston-based biotechnology company developing first-in-class treatments for obesity and glycemic control. A seasoned entrepreneur, Mr. Zohar has over 25 years experience in the launch and development of industry innovating companies. Prior to founding Gelesis, Mr. Zohar was a Co-Founder and Partner of PureTech Ventures, a Boston-based venture creation company focused on the translation of academic breakthroughs into commercially viable companies. In his role at PureTech he founded several companies and led the obesity initiative which engaged leading obesity experts to look at a broad landscape of technologies and approaches. This obesity initiative led to the formation of Gelesis. Prior to co-founding PureTech, Mr. Zohar co-founded and was the CEO of Zeta Ltd, a market leader in the Israeli edible oil market. Zohar was a pilot ranked Captain in the Israeli Defense Forces.
Managing Director & Founder, LaunchCapital
With a passion for working with industry disruptors and teams that have a strong business development focus, Elon has been involved in over 150 deals across a wide range of industries and geographies. His portfolio performance includes the sale of 20 companies since 2010 with an IRR that places LaunchCapital in the top 10% of venture funds worldwide. He holds an MBA from Yale School of Management and a BA in Economics from the George Washington University.
Meghan M. FitzGerald, DrPH
Operating Partner, L1 Health
Meghan serves as an Operating Partner at L1 Health LLC, Private Equity. With $2.5 billion of capital under management, L1 Health is the healthcare investment vehicle of LetterOne focused on long-term value creation. Prior to this Meghan was the EVP of Strategy, M&A and Health Policy at Cardinal Health and a member of the executive committee. Prior to this role she was the president of Cardinal Health Specialty Solutions, a specialty healthcare business that offers services for healthcare providers, payers, and pharmaceutical and biotech industries. Specialty Solutions is one of the fastest growing businesses at Cardinal Health. Prior to joining Cardinal Health, FitzGerald was senior vice president of New Markets International Division and Business Development at Medco Health Solutions, Inc. and held positions of increasing responsibility at Pfizer Global Pharmaceuticals. FitzGerald obtained a doctor of public health (DrPH) degree at New York Medical College, focusing on health policy. She earned a master of public health from Columbia University and a bachelor of nursing from Fairfield University.
Robert Forrester, LL.B
Robert is the President and CEO of Verastem (“VSTM”). Robert has over 15 years’ experience as the CEO, COO or CFO of both private and public life science companies with Forma Therapeutics, CombinatoRx (“CRXX” now “ZLCS”) and Coley (“COLY”, acquired by Pfizer). Robert was the co-founder and chairman of MoMelan, a medical device company, that was sold to KCI. Prior to his operating roles, Robert was a managing director of the Proprietary Investment Group at MeesPierson, part of the Fortis Group, investing in life science companies. Prior to MeesPierson, Robert worked for the investment banks, BZW (now Barclays Capital) and UBS, in the corporate finance groups undertaking M&A, and public and private finance transactions. Robert started his career as lawyer with Clifford Chance in London and Singapore. Robert has completed over $12 billion of transactions. He holds a LL.B. from Bristol University.
Stephen Muniz, JD
EVP, Legal and Operations, PureTech Health
Stephen is the Executive Vice President of Legal, Finance and Operations at PureTech and a member of the Board. Prior to joining PureTech, he was a partner in the Corporate Department of Locke Lord LLP, where he practiced law for 10 years. Stephen’s practice at Locke Lord focused on the representation of life science venture funds as well as their portfolio companies in general corporate matters and in investment and liquidity transactions. Stephen has a BA in Economics and Accounting from The College of the Holy Cross and a JD from New England School of Law where he graduated summa cum laude.
Raju Kucherlapati, PhD
Paul C. Cabot Professor of Genetics and a Professor of Medicine at Harvard Medical School
Raju was a founder and formerly a Board member of Abgenix (acquired by Amgen), and Millennium Pharmaceuticals (acquired by Takeda), and is currently the Paul C. Cabot Professor of Genetics and a Professor of Medicine at Harvard Medical School and was the first Scientific Director of the Harvard-Partners Center for Genetics and Genomics. He is a fellow of the American Association for the Advancement of Science and a member of the Institute of Medicine of the National Academy of Sciences. Dr. Kucherlapati’s laboratory at Harvard Medical School is involved in cloning and characterization of human disease genes with a focus on human syndromes with a significant cardiovascular involvement, use of genetic/genomic approaches to understand the biology of cancer and the generation and characterization of genetically modified mouse models for cancer and other human disorders. He served on the editorial board of the New England Journal of Medicine and was Editor in Chief of the journal Genomics.